ViiV Healthcare promotes HIV prevention and awareness among Black women with innovative campaigns.

ViiV Healthcare is distributing sex-positive activity books as part of its ongoing 'Risk to Reasons' campaign to help Black women feel empowered to have sex-positive conversations and reframe discussions around HIV prevention and services. Seagen has signed a licensing deal with Gracell Biotechnologies, granting the smaller partner rights to certain patents, but the scope of the deal and content of the Seagen patents remain unclear. Moderna may have to pay a hefty sum to settle complaints from two smaller companies that originally licensed the LNP tech to Moderna. Sanofi has lowered the price of its best-selling insulin product, Lantus, by 78% and set a $35 cap on out-of-pocket costs for Lantus for all patients with commercial insurance. Pfizer and Astellas are gunning to add a fourth indication to their cancer drug Xtandi with Phase III trial results released. Eli Lilly’s alopecia areata drug, Olumiant, is off to a good start with dermatologists.